Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic adipose tissue-derived mesenchymal stem cells (IdiPAZ)
- Development stage
- Unknown
- Lead developer
- Fundación de Investigación Biomédica. Instituto de Investigación Sanitaria d
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Local Injection
01
Overview
This investigational cell therapy, developed by the **Instituto de Investigación Hospital Universitario La Paz (IdiPAZ)** in Madrid, Spain, consists of expanded **allogeneic adipose tissue-derived mesenchymal stem cells (MSCs)**. It is being developed as an advanced therapy medicinal product (ATMP) for the stabilization of **abdominal aortic aneurysms (AAA)**. The treatment involves a single local injection of the cells (1x10^7 cells/kg) into the aneurysmal sac during an **endovascular aneurysm repair (EVAR)** procedure. The therapy leverages the immunomodulatory, anti-inflammatory, and regenerative properties of MSCs to reduce local inflammation and promote tissue repair within the excluded sac, potentially preventing sac expansion and complications such as endoleaks. It is currently being evaluated in a Phase IIa clinical trial (NCT04730232) comparing outcomes to historical cohorts.
- Other names
- allogeneic adipose-derived MSCsallogeneic adipose tissue-derived mesenchymal stem cells-Instituto de Investigación Hospital Universitario La Paz-abdominal aortic aneurysm
Beyond the preview
Go deeper on allogeneic adipose tissue-derived mesenchymal stem cells (IdiPAZ).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic adipose tissue-derived mesenchymal stem cells (IdiPAZ).